- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05269082
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
In Vitro Assessment of Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood From Patients at Increased Risk of Developing Hypersensitivity Reactions
The aim of this study is to find out whether TAK-880 creates hypersensitivity reactions compared to Gammagard S/D by testing blood taken from participants who have a higher risk of becoming hypersensitive to immunoglobulin products.
This study is about collecting data available in the participant's medical record. No study medicines will be provided to participants in this study. Each participant will fill out a study questionnaire during a routine doctor visit. Blood will be taken from participants who have a higher risk of developing hypersensitivity reactions to immunoglobulin products.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28401
- PPD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- At least 2 years of age except PID participants with selective IgA deficiency (the lower age limit in this group of participants is 4 years of age).
- Participant has previously received at least one infusion of Gammagard S/D prescribed for any approved indication (PID, B-cell Chronic Lymphocytic Leukemia, Idiopathic Thrombocytopenic Purpura, Kawasaki Syndrome) OR PID participant with IgA deficiency (serum IgA level of < 7 mg/dL (0.07 g/L) or below the detectable limit in participants older than 4 years) and has received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D).
- Participant/legally authorized representative is willing to sign an informed consent form or assent form as applicable and is able to comply with the requirements of the protocol.
Exclusion criteria:
-There are no applicable exclusion criteria for this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1
Pediatric and adult participants who are on Gammagard S/D prescribed for any approved indication will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
|
This is a non-interventional study.
|
Cohort 2
Pediatric and adult participants who were previously treated with Gammagard S/D prescribed for any approved indication and are on another human immunoglobulin treatment will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
|
This is a non-interventional study.
|
Cohort 3
Pediatric and adult primary immunodeficiency (PID) participants with immunoglobin A (IgA) deficiency who have a serum IgA level of less than (<) 7 milligrams per deciliter (mg/dL) (0.07 grams/liter [g/L]) or below the detectable limit and have received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D) will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
|
This is a non-interventional study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with In Vitro Hypersensitivity to TAK-880 in Comparison to Gammagard S/D
Time Frame: Up to approximately 6 months
|
Levels of in vitro hypersensitivity to TAK-880 in comparison to a reference product (Gammagard S/D) using hypersensitivity assays to address (but not limited to) immune cell activation and cytokine secretion, stratified by anti-IgA antibody levels will be evaluated during the study.
Number of participants with In vitro hypersensitivity to TAK-880 in comparison to Gammagard S/D will be reported.
|
Up to approximately 6 months
|
Number of Participants with Drug Hypersensitive Reactions to Immunoglobulin Products for Cohort 1 and 2
Time Frame: Up to approximately 6 months
|
Number of Participants with drug hypersensitive reactions to immunoglobulin products who have previously received at least one infusion of Gammagard S/D in Cohorts 1 and 2 will be reported.
|
Up to approximately 6 months
|
Number of Participants with History to Drug Hypersensitive Reactions
Time Frame: Up to approximately 6 months
|
Number of participants with history to drug hypersensitive reactions will be reported.
|
Up to approximately 6 months
|
Number of Participants Categorized by Clinical Characteristics
Time Frame: Up to approximately 6 months
|
Number of participants categorized by clinical characteristics such as geographic location of residency, level of education will be reported.
|
Up to approximately 6 months
|
Number of Participants Categorized by Treatment Patterns
Time Frame: Up to approximately 6 months
|
Number of participants categorized by treatment patterns will be reported.
|
Up to approximately 6 months
|
Health Related Quality of Life Measured by 36-Item Short Form Health Survey (SF-36)
Time Frame: Up to approximately 6 months
|
SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL).
SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning [ranges from 1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time: to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]).
Four domains comprised physical component summary (PCS) score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised mental component summary (MCS) score (vitality, social functioning, role-emotional, mental health).
The total scores range from 0 to 100.
Higher scores indicate better quality of life.
|
Up to approximately 6 months
|
Health Related Quality of Life Measured by EuroQol 5 Dimensions Questionnaire (EQ-5D)
Time Frame: Up to approximately 6 months
|
EQ-5D is a well-validated, general preference-based, health-related QoL instrument.
The EQ-5D encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression.
Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5).
Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state.
For each participant, an index value is determined from a published country-specific value set.
This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions.
A positive change from baseline indicates improvement.
|
Up to approximately 6 months
|
Health Related Quality of Life Measured by Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Validated Instrument for Cohort 1 and 2
Time Frame: Up to approximately 6 months
|
TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication.
The three domains assessed are effectiveness (3 items), convenience (3 items), and global satisfaction (3 items).
Scores for each domain are calculated by adding up the items in each domain and then transforming the composite score into a value ranging from 0 to 100.
Higher score indicated greater satisfaction in that domain.
|
Up to approximately 6 months
|
Patient Reported Outcomes (PROs) Using PID-Specific Life Quality Index (LQI) Questionnaire for Cohort 1 and 2
Time Frame: Up to approximately 6 months
|
The PID-LQI questionnaire involves 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items).
Items are rated on a 7-point Likert-type scale ranging from 1: "Extremely poor" to 7: "Extremely good".
The items measure the impact of the treatment on patient quality of life: factor I (treatment interference), factor II (therapy-related problems), factor III (therapy settings).
Results range from 0 (maximal concern) to 100 (no concern).
PROs using PID-specific LQI questionnaire in Cohort 1 and 2 will be reported.
|
Up to approximately 6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-880-5001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Hypersensitivity
-
Central Hospital, Nancy, FranceRecruiting
-
Peking Union Medical College HospitalUnknownDrug Hypersensitivity ReactionChina
-
University Hospital, Strasbourg, FranceRecruitingHypersensitivity, DrugFrance
-
Suodi ZHAIPeking University; The Second Hospital of Hebei Medical University; West China... and other collaboratorsCompletedAdverse Drug Reaction | Drug AllergyChina
-
University Hospital, AntwerpNot yet recruitingHypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic ReactionBelgium
-
University of Southern CaliforniaEnrolling by invitationDRESS Syndrome | Drug-Induced Hypersensitivity SyndromeUnited States
-
University Hospital, GrenobleTerminatedAllergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross ReactionFrance
-
Istanbul University - Cerrahpasa (IUC)Completed
-
University Hospital, Gentofte, CopenhagenResearch Unit Of General Practice, CopenhagenCompleted
-
Central South UniversityUnknownGeneral Anesthetic Drug AllergyChina
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of PittsburghCompletedChronic Low Back PainUnited States